Alphamab Oncology (9966.HK)

HKD 5.0

(-3.47%)

Operating Income Summary of Alphamab Oncology

Alphamab Oncology's latest annual operating income in 2023 was -305.55 Million CNY , up 25.22% from previous year.
Alphamab Oncology's latest quarterly operating income in 2024 Q2 was -86.49 Million CNY , down 0.0% from previous quarter.
Alphamab Oncology reported an annual operating income of -432.37 Million CNY in 2022, down -4.03% from previous year.
Alphamab Oncology reported an annual operating income of -415.61 Million CNY in 2021, down -1.51% from previous year.
Alphamab Oncology reported a quarterly operating income of -124.62 Million CNY for 2023 Q2, down 0.0% from previous quarter.
Alphamab Oncology reported a quarterly operating income of -323.32 Million CNY for 2023 FY, up 25.22% from previous quarter.

Annual Operating Income Chart of Alphamab Oncology (2023 - 2017)

Historical Annual Operating Income of Alphamab Oncology (2023 - 2017)

Year	Operating Income	Operating Income Growth
2023	-305.55 Million CNY	25.22%
2022	-432.37 Million CNY	-4.03%
2021	-415.61 Million CNY	-1.51%
2020	-409.44 Million CNY	50.62%
2019	-829.13 Million CNY	-529.52%
2018	-131.7 Million CNY	-103.2%
2017	-64.81 Million CNY	0.0%

Year	Operating Income	Operating Income Growth
2024 Q2	-86.49 Million CNY	0.0%
2023 Q2	-124.62 Million CNY	0.0%
2023 FY	-323.32 Million CNY	25.22%
2023 Q4	-198.73 Million CNY	0.0%
2022 Q4	-210.62 Million CNY	0.0%
2022 FY	-432.37 Million CNY	-4.03%
2022 Q2	-221.74 Million CNY	0.0%
2021 Q2	-270.07 Million CNY	0.0%
2021 Q4	-145.54 Million CNY	0.0%
2021 FY	-415.61 Million CNY	-1.51%
2020 FY	-409.44 Million CNY	50.62%
2020 Q4	-235.14 Million CNY	0.0%
2020 Q2	-174.3 Million CNY	0.0%
2019 FY	-829.13 Million CNY	-529.52%
2019 Q4	-201.54 Million CNY	0.0%
2019 Q2	-77.85 Million CNY	62.44%
2019 Q1	-207.28 Million CNY	-265.39%
2018 Q1	-37.08 Million CNY	0.0%
2018 Q2	-35.47 Million CNY	4.35%
2018 FY	-131.7 Million CNY	-103.2%
2018 Q4	-56.72 Million CNY	0.0%
2017 Q2	-8.26 Million CNY	0.0%
2017 Q1	-8.26 Million CNY	0.0%
2017 FY	-64.81 Million CNY	0.0%
2017 Q4	-37.08 Million CNY	0.0%
2016 Q4	-8.26 Million CNY	0.0%

Peer Operating Income Comparison of Alphamab Oncology

Name	Operating Income	Operating Income Difference
Uni-Bio Science Group Limited	67.76 Million HKD	550.877%
CK Life Sciences Int'l., (Holdings) Inc.	897.95 Million HKD	134.027%